INTRAVENOUS VERNAKALANT FOR THE TREATMENT OF NEW-ONSET ATRIAL FIBRILLATION IN THE EMERGENCY DEPARTMENT

Vernakalant is a novel antiarrhythmic agent with a preferential effect on atrial tissue and limited action on ventricular tissue. Intravenous vernakalant effectively converts recent onset atrial fibrillation; conversion is usually achieved quickly with a short half-life and allows early hospital